1. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. (13th August 2019) Authors: Chaput, N; Lepage, P; Coutzac, C; Soularue, E; Le Roux, K; Monot, C; Boselli, L; Routier, E; Cassard, L; Collins, M; Vaysse, T; Marthey, L; Eggermont, A; Asvatourian, V; Lanoy, E; Mateus, C; Robert, C; Carbonnel, F Journal: Annals of oncology Issue: Volume 30:Number 12(2019) Page Start: 2012 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P664 Association between pharmacologic loss of response profile of anti-TNF and clinical outcome with vedolizumab. (16th January 2018) Authors: Berthaux, J; DeBoissieu, P; Amiot, A; Vaysse, T; Carbonnel, F; Collins, M Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S446 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P711 The real-life experience of vedolizumab therapy in the OBSERV-IBD cohort: a 3-year prospective observational multi-centre cohort study. (25th January 2019) Authors: Amiot, A; Serrero, M; Peyrin-Biroulet, L; Filippi, J; Pariente, B; Roblin, X; Buisson, A; Stefanescu, C; Trang-Poisson, C; Altwegg, R; Marteau, P; Vaysse, T; Bourrier, A; Nancey, S; Laharie, D; Allez, M; Savoye, G; Moreau, J; Vuitton, L; Viennot, S Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S476 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗